OX40/CD134

The OX40 receptor, also known as CD134, is a tumor necrosis superfamily receptor (TNSFR4) that is recognized as a costimulatory receptor for T cells. OX40 is predominantly expressed on activated CD4 T cells. OX40 has been shown to be essential for the regulation, differentiation, and survival of conventional CD4 and CD8 T cells.¹ Multiple studies have demonstrated that activation of the OX40 receptor via ligand or agonist (antibody) binding enhances T cell-mediated antitumor immunity.^2-4 

Based on its critical co-stimulatory role in T-cell based anti-tumor immunity, OX40 has been identified as a promising therapeutic target in late stage cancers. Additional studies have suggested the utility of combination therapies involving OX40 activation in conjunction with CTLA-4 or PD-1 suppression: enabling the proliferation of T-cells while removing the suppressive action of “immune checkpoint inhibitors”.^3,4

Specifications

1. Toennies HM, et al. Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms. J Leukoc Biol. 2004 Feb;75(2):350-7.
2. Curti BD, et al. OX40 is a potent immune-stimulating target in latestage cancer patients. Cancer Res. 2013 Dec 15; 73(24):7189-98.
3. Linch SN, et al. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol. 2015; 5:34.
4. Jeong S, Park SH. Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy. Immune Netw. 2020 Feb;
20(1):e3.
5. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
6. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.